Which groups are not suitable for using Tilpotide/Mufenda weight loss drugs?

As a new generation of dual-target metabolism regulating drugs, Tirzepatide has attracted much attention due to its significant effects on weight management and blood sugar improvement (type 2 diabetes). However, weight loss drugs are not suitable for everyone. There are certain restrictions on the use of tilpotide, and blind use may bring risks.

First of all, pregnant women and lactating women are prohibited groups. Tilpotide can change the nutritional supply of the mother and fetus by affecting metabolic hormone levels. There is currently a lack of safety data on its safety during pregnancy and lactation, and it may have adverse effects on the fetus or infant. Therefore, people planning to become pregnant or already pregnant should avoid use.

Secondly, it is contraindicated for people with a personal or family history of medullary thyroid cancer (MTC), or multiple endocrine neoplasia syndrome type 2 (MEN2). This is because animal experiments suggest that GLP-1 receptor agonists may increase the risk of thyroid C-cell tumors. Although the evidence in humans is limited, this group of people should still be strictly excluded clinically.

Third, it is not recommended for patients with severe gastrointestinal diseases. Tilpotide will delay gastric emptying, and some patients may experience nausea, vomiting, diarrhea and other discomforts. For patients with severe gastroparesis or risk of intestinal obstruction, the condition may be aggravated. In addition, patients with a history of acute pancreatitis should also be cautious as such drugs may induce or worsen pancreatitis.

Fourth, patients with severe renal insufficiency or liver dysfunction should use it with caution. Although tilpotide is primarily degraded by proteases rather than directly eliminated by the kidneys, its metabolic regulatory effects may affect water and electrolyte balance, posing an increased risk to patients with severe organ dysfunction.

In addition, people with insufficient psychological preparation or poor compliance, that is, patients who cannot adhere to lifestyle management for a long time and are easy to stop taking medication on their own, are not suitable for rash use. Because Tilpotide is not a simple "quick-acting slimming shot", but requires long-term metabolic intervention in conjunction with diet and exercise. Once the drug is discontinued or the lifestyle rebounds, the weight is likely to return.

Reference materials:https://www.drugs.com/tirzepatide.html